Ozenoxacin may effectively treat impetigo without contributing to antimicrobial resistance (AMR), according to a review published in the April issue of the Journal of Drugs in Dermatology.

Lawrence A. Schachner, M.D., from the Leonard M. Miller School of Medicine at the University of Miami, and colleagues conducted a literature review to assess the status of AMR to current topical antibiotics in impetigo, current therapeutic behavior, and concordance with antimicrobial stewardship principles.

Based on 19 articles meeting inclusion criteria, the researchers found that few studies have attempted to evaluate topical antibiotic prescribing practices for impetigo treatment. Many of the topical impetigo treatments currently in use have developed resistance. The appropriate use of topical ozenoxacin can help eradicate impetigo while minimizing AMR, given its low capacity for developing resistance.

"Stewardship programs are required to educate general practitioners, pediatricians, and dermatologists on the topic of AMR in skin and soft tissue infections," the authors write.

The study was funded by Biofrontera Inc., the manufacturer of ozenoxacin.

Abstract/Full Text (subscription or payment may be required)